OMIC Singular Genomics
- 0.400
- -0.007-1.74%
Singular Genomics News
Singular Genomics Sys Analyst Ratings
Singular Genomics Sys Analyst Ratings
Hold Rating on Singular Genomics Systems (OMIC) Amid Q3 Underperformance and Strategy Shift
UBS Adjusts Singular Genomics Systems Price Target to $0.40 From $0.90, Maintains Neutral Rating
Goldman Sachs Maintains Neutral on Singular Genomics Sys, Lowers Price Target to $1
Singular Genomics Sys Analyst Ratings
UBS Adjusts Singular Genomics Systems Price Target to $1.25 From $2.25, Maintains Neutral Rating
UBS Adjusts Singular Genomics Systems Price Target to $2.25 From $2.50, Maintains Neutral Rating
UBS Adjusts Singular Genomics Systems Price Target to $2.50 From $4.50, Maintains Neutral Rating
Singular Genomics Sys Analyst Ratings
Goldman Sachs Maintains Neutral on Singular Genomics Sys, Lowers Price Target to $3
Singular Genomics Systems (OMIC) Was Downgraded to a Hold Rating at J.P. Morgan
Singular Genomics Systems (OMIC) Was Downgraded to a Hold Rating at J.P. Morgan
Singular Genomics Systems Cut to Neutral From Buy by UBS
Singular Genomics Systems Price Target Cut to $4.50/Share From $10.00 by UBS
Singular Genomics Sys Analyst Ratings
UBS Downgrades Singular Genomics Sys to Neutral, Lowers Price Target to $4.5
Singular Genomics Systems (OMIC) Was Downgraded to a Hold Rating at J.P. Morgan
Singular Genomics Systems Price Target Announced at $3.00/Share by B of A Securities
Singular Genomics Systems Cut to Underperform From Buy by B of A Securities
Analysis
Price Target
No Data
